We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Smartphone Device Created Performs Blood Tests

By LabMedica International staff writers
Posted on 03 Apr 2014
Print article
Image: Schematics of the Qloudlab smartphone device (Photo courtesy of Alain Herzog).
Image: Schematics of the Qloudlab smartphone device (Photo courtesy of Alain Herzog).
A smartphone device has been created that can perform blood tests—an innovation that could improve the quality of life for people undergoing treatment for the prevention of blood clots.

The formation of blood clots in the arteries and veins can increase the risk of heart attack and stroke, and individuals at high risk of blood clots are often treated with anticoagulants drugs that thin the blood and prevent the clotting process.

Bioengineers at the École Polytechnique Fédérale de Lausanne (EPFL; Switzerland) microengineering laboratory have created a device that could allow patients undergoing anticoagulant therapy to self-monitor. The gadget consists of a small single-use film that is attached to the screen of a smartphone. The film is made of a microstructured plastic layer that is a few micrometers thick.

When blood enters the film through capillary action, the device can detect a molecule present in blood that initiates coagulation, the process by which blood forms clots. The phone is then able to interpret the results by analyzing interferences in the electric field on the surface of the smartphone's screen. This is a process similar to what happens when a finger comes into contact with the screen of a smartphone. The results are then sent to a specific smartphone application, created by Qloudlab (Lausanne, Switzerland), the start-up company based at EPFL. This data can then be sent directly to a physician, who can assess whether a patient’s treatment needs to be modified.

Qloudlab has recently applied for a patent for the device, and the creators have recently received funding from Venture Kick (St. Gallen, Switzerland) that has allowed them to recruit a biochemist. The team hopes that by the end of next year, they will have shown that the device is as reliable as a laboratory test and can progress toward commercialization. Arther Queval, MSc, the founder of Qloudlab, said, “Such a test will significantly improve the quality of life for people undergoing this kind of treatment."

Related Links:

École Polytechnique Fédérale de Lausanne
Qloudlab 
Venture Kick


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.